Table 1 Characteristics of PLWH and HIV-negative people enrolled in the study (N = 2,254)
|  | PLWH (n = 890) | HIV-negative (n = 1364) | p value |
|---|---|---|---|
Male | 753 (84.6) | 375 (27.5) |  < 0.001 |
Age, years, median (IQR) | 36 (30–47.25) | 36 (31–45) | 0.613 |
COVID-19 vaccination, n (%) |  |  |  < 0.001 |
 One dose/two doses | 166 (18.6) | 282 (20.7) |  |
 Three doses | 655 (73.6) | 884 (64.8) |  |
 Four dosesa | 9 (1.0) | 112 (8.2) |  |
 Unvaccinated | 60 (6.7) | 86 (6.3) |  |
 Diabetes, n (%) | 27 (3.0) | 34 (2.5) | 0.507 |
 Cardiovascular and cerebrovascular diseases, n (%) | 73 (8.2) | 129 (9.4) | 0.327 |
 Chronic lung diseases, n (%) | 26 (2.9) | 31 (2.3) | 0.340 |
 Chronic kidney diseases, n (%) | 12 (1.3) | 17 (1.2) | 0.850 |
 Chronic liver Diseases, n (%) | 42 (4.7) | 29 (2.1) | 0.001 |
CD4 T count [cells/µL, n (%)] | |||
 0–199 | 71 (8.0) | ·· | ·· |
 200–349 | 144 (16.2) | ·· | ·· |
 350–499 | 203 (22.8) | ·· | ·· |
  ≥ 500 | 332 (37.3) | ·· | ·· |
Unknown | 140 (15.7) | ·· | ·· |
HIV viral load, n (%) | |||
 Undetectable | 620 (69.6) | ·· | ·· |
 Detectable | 105 (11.8) | ·· | ·· |
 Unknown | 165 (18.5) | ·· | ·· |
On ART, n (%) | 856 (96.2) | ·· | ·· |
ART regimens, n (%) | |||
 None | 34 (3.8) | ·· | ·· |
 NNRTI | 464 (52.1) | ·· | ·· |
 LPV/r | 65 (7.3) | ·· | ·· |
 INSTIs | 377 (42.3) | ·· | ·· |